View Future GrowthAkzo Nobel 과거 순이익 실적과거 기준 점검 3/6Akzo Nobel의 수입은 연평균 -12.2%의 비율로 감소해 온 반면, Chemicals 산업은 수입이 연평균 4.4% 감소했습니다. 매출은 연평균 2.1%의 비율로 증가해 왔습니다. Akzo Nobel의 자기자본이익률은 12.9%이고 순이익률은 6.3%입니다.핵심 정보-12.24%순이익 성장률-9.65%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률2.07%자기자본이익률12.90%순이익률6.26%다음 순이익 업데이트22 Jul 2026최근 과거 실적 업데이트공고 • Jun 25Akzo Nobel N.V. to Report Q2, 2026 Results on Jul 22, 2026Akzo Nobel N.V. announced that they will report Q2, 2026 results on Jul 22, 2026Reported Earnings • Apr 22First quarter 2026 earnings released: EPS: €0.54 (vs €0.63 in 1Q 2025)First quarter 2026 results: EPS: €0.54 (down from €0.63 in 1Q 2025). Revenue: €2.39b (down 8.7% from 1Q 2025). Net income: €93.0m (down 13% from 1Q 2025). Profit margin: 3.9% (down from 4.1% in 1Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.공고 • Apr 08Akzo Nobel N.V. to Report Q1, 2026 Results on Apr 22, 2026Akzo Nobel N.V. announced that they will report Q1, 2026 results on Apr 22, 2026Reported Earnings • Feb 26Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.Reported Earnings • Feb 04Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.공고 • Jan 20Akzo Nobel N.V. to Report Q4, 2025 Results on Feb 03, 2026Akzo Nobel N.V. announced that they will report Q4, 2025 results on Feb 03, 2026모든 업데이트 보기Recent updates공고 • 16hNippon Paint Holdings Co., Ltd. (TSE:4612) proposed to acquire Decorative Paints Business of Akzo Nobel N.V. (ENXTAM:AKZA) for €7.5 billion.Nippon Paint Holdings Co., Ltd. (TSE:4612) proposed to acquire Decorative Paints Business of Akzo Nobel N.V. (ENXTAM:AKZA) for €7.5 billion on July 12, 2026. The consideration of €7.5 billion ($8.55 billion) will be paid in cash. however, no specific matters regarding the acquisition have been decided at this time. Nippon Paint Holdings Co., Ltd. will promptly disclose any material fact that becomes subject to disclosure in the future.공고 • Jun 25Akzo Nobel N.V. to Report Q2, 2026 Results on Jul 22, 2026Akzo Nobel N.V. announced that they will report Q2, 2026 results on Jul 22, 2026공고 • May 28Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) cancelled the acquisition of Akzo Nobel N.V. (ENXTAM:AKZA) for €12.5 billion.Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) submitted a conditional and non-binding proposal to acquire Akzo Nobel N.V. (ENXTAM:AKZA) for €12.5 billion on April 29, 2026. Under the terms of the acquisition, Nippon Paint Holdings Co., Ltd. and The Sherwin-Williams Company will pay €73 in cash per share for all of the issued and outstanding shares of AkzoNobel. Upon completion of the proposed transaction, Nippon Paint would retain AkzoNobel's Decorative Paints and Industrial Coatings businesses, while AkzoNobel's Automotive & Specialty Coatings, Marine & Protective Coatings and Powder Coatings businesses would be sold separately to Sherwin-Williams. Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) cancelled the acquisition of Akzo Nobel N.V. (ENXTAM:AKZA) on May 1, 2026. The Board of Management and the Supervisory Board carefully reviewed and considered the Proposal, together with their respective financial and legal advisors, in line with their fiduciary duties. The Boards concluded that the Proposal did not qualify, nor was it reasonably expected to qualify, as a 'Superior Proposal' (as defined in the merger agreement between AkzoNobel and Axalta), considering a variety of aspects of the Proposal. AkzoNobel Boards unanimously continue to recommend the merger between AkzoNobel and Axalta.Reported Earnings • Apr 22First quarter 2026 earnings released: EPS: €0.54 (vs €0.63 in 1Q 2025)First quarter 2026 results: EPS: €0.54 (down from €0.63 in 1Q 2025). Revenue: €2.39b (down 8.7% from 1Q 2025). Net income: €93.0m (down 13% from 1Q 2025). Profit margin: 3.9% (down from 4.1% in 1Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.Upcoming Dividend • Apr 20Upcoming dividend of €1.54 per shareEligible shareholders must have bought the stock before 27 April 2026. Payment date: 06 May 2026. Payout ratio is a comfortable 53% and this is well supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of German dividend payers (4.5%). In line with average of industry peers (3.7%).공고 • Apr 08Akzo Nobel N.V. to Report Q1, 2026 Results on Apr 22, 2026Akzo Nobel N.V. announced that they will report Q1, 2026 results on Apr 22, 2026New Risk • Mar 20New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 56% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Feb 26Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.Buy Or Sell Opportunity • Feb 26Now 20% undervaluedOver the last 90 days, the stock has risen 7.9% to €59.46. The fair value is estimated to be €74.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 6.6%. For the next 3 years, revenue is forecast to grow by 4.3% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.New Risk • Feb 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 191% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Feb 04Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.공고 • Feb 04Akzo Nobel N.V., Annual General Meeting, Apr 23, 2026Akzo Nobel N.V., Annual General Meeting, Apr 23, 2026.공고 • Jan 20Akzo Nobel N.V. to Report Q4, 2025 Results on Feb 03, 2026Akzo Nobel N.V. announced that they will report Q4, 2025 results on Feb 03, 2026공고 • Nov 18+ 3 more updatesAkzo Nobel N.V. and Axalta Coating Systems Ltd. Announce Board and Executive Changes to Combined CompanyAkzo Nobel N.V. and Axalta Coating Systems Ltd. announced that they have entered into a definitive agreement to combine in an all-stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Upon closing, the combined company will have a one-tier Board, led by Rakesh Sachdev, current Chair of the Axalta Board of Directors. Ben Noteboom, current Chairman of the AkzoNobel Supervisory Board, will serve as Vice Chair. The Board will be composed of 11 directors – four from each company and three independent members. Of the 11 Board members, two will be executive directors and nine will be non-executive directors. Each company expects to hold its respective Extraordinary General Meeting of Shareholders tentatively in mid-2026. Current AkzoNobel CEO, Greg Poux-Guillaume, will serve as CEO of the combined company, and current Axalta CEO, Chris Villavarayan, will serve as Deputy CEO. Current Axalta SVP and CFO, Carl Anderson, will serve as the CFO of the combined company.New Risk • Oct 25New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 5.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Shares are highly illiquid. Minor Risks Dividend is not well covered by earnings (dividend per share is over 5x earnings per share). Profit margins are more than 30% lower than last year (0.6% net profit margin).Reported Earnings • Oct 25Third quarter 2025 earnings released: €1.13 loss per share (vs €0.95 profit in 3Q 2024)Third quarter 2025 results: €1.13 loss per share (down from €0.95 profit in 3Q 2024). Revenue: €2.55b (down 4.5% from 3Q 2024). Net loss: €193.0m (down 218% from profit in 3Q 2024). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.매출 및 비용 세부 내역Akzo Nobel가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:AKU1 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 269,9316222,91827431 Dec 2510,1586362,96927430 Sep 2510,405593,03629630 Jun 2510,5264153,04529631 Mar 2510,6844673,12029631 Dec 2410,7115423,09129630 Sep 2410,6215653,04827030 Jun 2410,6945923,07127031 Mar 2410,6515342,99227031 Dec 2310,6684472,96227030 Sep 2310,7454112,97625830 Jun 2310,8663092,97625831 Mar 2310,9783032,98325831 Dec 2210,8463622,93925830 Sep 2210,6435402,86423030 Jun 2210,1916162,76623031 Mar 229,8497582,66123031 Dec 219,5878232,61023030 Sep 219,3938052,61823830 Jun 219,2598662,59923831 Mar 218,7357412,54723831 Dec 208,5306372,57923830 Sep 208,5635442,59526230 Jun 208,6854812,67726231 Mar 209,1495672,76426231 Dec 199,2765172,83326230 Sep 199,3424772,92926430 Jun 199,2704632,91826431 Mar 199,2653543,02826431 Dec 189,2564003,04426430 Sep 189,2313933,00527030 Jun 189,3243653,06827031 Mar 189,4114263,05027031 Dec 179,6124393,10727030 Sep 176,0221072,32925730 Jun 177,2032722,60325731 Mar 178,3814172,88825731 Dec 169,4345343,13825730 Sep 1614,3001,0324,15834730 Jun 1614,4601,0314,19434731 Mar 1614,6981,0514,25334731 Dec 1514,8599734,27934730 Sep 1514,8177724,295363양질의 수익: AKU1는 €357.0M 규모의 큰 일회성 이익이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: AKU1의 현재 순 이익률 (6.3%)은 지난해 (4.4%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: AKU1의 수익은 지난 5년 동안 연평균 12.2% 감소했습니다.성장 가속화: 지난 1년간 AKU1 의 수익 증가율(33.2%)은 연간 평균(-12.2%)을 초과합니다.수익 대 산업: AKU1의 지난 1년 수익 증가율(33.2%)은 Chemicals 업계의 -13.5%를 상회했습니다.자기자본이익률높은 ROE: AKU1의 자본 수익률(12.9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 04:39종가2026/07/13 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Akzo Nobel N.V.는 41명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Katie RichardsBarclaysJennifer BarkerBarclaysRobert BateBarclays38명의 분석가 더 보기
공고 • Jun 25Akzo Nobel N.V. to Report Q2, 2026 Results on Jul 22, 2026Akzo Nobel N.V. announced that they will report Q2, 2026 results on Jul 22, 2026
Reported Earnings • Apr 22First quarter 2026 earnings released: EPS: €0.54 (vs €0.63 in 1Q 2025)First quarter 2026 results: EPS: €0.54 (down from €0.63 in 1Q 2025). Revenue: €2.39b (down 8.7% from 1Q 2025). Net income: €93.0m (down 13% from 1Q 2025). Profit margin: 3.9% (down from 4.1% in 1Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.
공고 • Apr 08Akzo Nobel N.V. to Report Q1, 2026 Results on Apr 22, 2026Akzo Nobel N.V. announced that they will report Q1, 2026 results on Apr 22, 2026
Reported Earnings • Feb 26Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Feb 04Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.
공고 • Jan 20Akzo Nobel N.V. to Report Q4, 2025 Results on Feb 03, 2026Akzo Nobel N.V. announced that they will report Q4, 2025 results on Feb 03, 2026
공고 • 16hNippon Paint Holdings Co., Ltd. (TSE:4612) proposed to acquire Decorative Paints Business of Akzo Nobel N.V. (ENXTAM:AKZA) for €7.5 billion.Nippon Paint Holdings Co., Ltd. (TSE:4612) proposed to acquire Decorative Paints Business of Akzo Nobel N.V. (ENXTAM:AKZA) for €7.5 billion on July 12, 2026. The consideration of €7.5 billion ($8.55 billion) will be paid in cash. however, no specific matters regarding the acquisition have been decided at this time. Nippon Paint Holdings Co., Ltd. will promptly disclose any material fact that becomes subject to disclosure in the future.
공고 • Jun 25Akzo Nobel N.V. to Report Q2, 2026 Results on Jul 22, 2026Akzo Nobel N.V. announced that they will report Q2, 2026 results on Jul 22, 2026
공고 • May 28Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) cancelled the acquisition of Akzo Nobel N.V. (ENXTAM:AKZA) for €12.5 billion.Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) submitted a conditional and non-binding proposal to acquire Akzo Nobel N.V. (ENXTAM:AKZA) for €12.5 billion on April 29, 2026. Under the terms of the acquisition, Nippon Paint Holdings Co., Ltd. and The Sherwin-Williams Company will pay €73 in cash per share for all of the issued and outstanding shares of AkzoNobel. Upon completion of the proposed transaction, Nippon Paint would retain AkzoNobel's Decorative Paints and Industrial Coatings businesses, while AkzoNobel's Automotive & Specialty Coatings, Marine & Protective Coatings and Powder Coatings businesses would be sold separately to Sherwin-Williams. Nippon Paint Holdings Co., Ltd. (TSE:4612) and The Sherwin-Williams Company (NYSE:SHW) cancelled the acquisition of Akzo Nobel N.V. (ENXTAM:AKZA) on May 1, 2026. The Board of Management and the Supervisory Board carefully reviewed and considered the Proposal, together with their respective financial and legal advisors, in line with their fiduciary duties. The Boards concluded that the Proposal did not qualify, nor was it reasonably expected to qualify, as a 'Superior Proposal' (as defined in the merger agreement between AkzoNobel and Axalta), considering a variety of aspects of the Proposal. AkzoNobel Boards unanimously continue to recommend the merger between AkzoNobel and Axalta.
Reported Earnings • Apr 22First quarter 2026 earnings released: EPS: €0.54 (vs €0.63 in 1Q 2025)First quarter 2026 results: EPS: €0.54 (down from €0.63 in 1Q 2025). Revenue: €2.39b (down 8.7% from 1Q 2025). Net income: €93.0m (down 13% from 1Q 2025). Profit margin: 3.9% (down from 4.1% in 1Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.
Upcoming Dividend • Apr 20Upcoming dividend of €1.54 per shareEligible shareholders must have bought the stock before 27 April 2026. Payment date: 06 May 2026. Payout ratio is a comfortable 53% and this is well supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of German dividend payers (4.5%). In line with average of industry peers (3.7%).
공고 • Apr 08Akzo Nobel N.V. to Report Q1, 2026 Results on Apr 22, 2026Akzo Nobel N.V. announced that they will report Q1, 2026 results on Apr 22, 2026
New Risk • Mar 20New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 56% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Feb 26Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.
Buy Or Sell Opportunity • Feb 26Now 20% undervaluedOver the last 90 days, the stock has risen 7.9% to €59.46. The fair value is estimated to be €74.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 6.6%. For the next 3 years, revenue is forecast to grow by 4.3% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
New Risk • Feb 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 191% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Feb 04Full year 2025 earnings released: EPS: €3.72 (vs €3.18 in FY 2024)Full year 2025 results: EPS: €3.72 (up from €3.18 in FY 2024). Revenue: €10.2b (down 5.2% from FY 2024). Net income: €636.0m (up 17% from FY 2024). Profit margin: 6.3% (up from 5.1% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.
공고 • Feb 04Akzo Nobel N.V., Annual General Meeting, Apr 23, 2026Akzo Nobel N.V., Annual General Meeting, Apr 23, 2026.
공고 • Jan 20Akzo Nobel N.V. to Report Q4, 2025 Results on Feb 03, 2026Akzo Nobel N.V. announced that they will report Q4, 2025 results on Feb 03, 2026
공고 • Nov 18+ 3 more updatesAkzo Nobel N.V. and Axalta Coating Systems Ltd. Announce Board and Executive Changes to Combined CompanyAkzo Nobel N.V. and Axalta Coating Systems Ltd. announced that they have entered into a definitive agreement to combine in an all-stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Upon closing, the combined company will have a one-tier Board, led by Rakesh Sachdev, current Chair of the Axalta Board of Directors. Ben Noteboom, current Chairman of the AkzoNobel Supervisory Board, will serve as Vice Chair. The Board will be composed of 11 directors – four from each company and three independent members. Of the 11 Board members, two will be executive directors and nine will be non-executive directors. Each company expects to hold its respective Extraordinary General Meeting of Shareholders tentatively in mid-2026. Current AkzoNobel CEO, Greg Poux-Guillaume, will serve as CEO of the combined company, and current Axalta CEO, Chris Villavarayan, will serve as Deputy CEO. Current Axalta SVP and CFO, Carl Anderson, will serve as the CFO of the combined company.
New Risk • Oct 25New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 5.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Shares are highly illiquid. Minor Risks Dividend is not well covered by earnings (dividend per share is over 5x earnings per share). Profit margins are more than 30% lower than last year (0.6% net profit margin).
Reported Earnings • Oct 25Third quarter 2025 earnings released: €1.13 loss per share (vs €0.95 profit in 3Q 2024)Third quarter 2025 results: €1.13 loss per share (down from €0.95 profit in 3Q 2024). Revenue: €2.55b (down 4.5% from 3Q 2024). Net loss: €193.0m (down 218% from profit in 3Q 2024). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany.